Prometheus Biosciences Inc

RXDX | $199.92 0.02% 1.9M

(0.0% 1d) (0.0% 1m) (3.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-47.11% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 9,558,822,541
https://www.prometheusbiosciences.com
Sec Filling | Patents | n/a employees

Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.

diagnostics gastrointestinal treatment

add to watch list Paper trade email alert is off

Biomea Fusion Inc

BMEA | $10.87 -2.6% -2.67% 1.3M

Professional, Scientific, and T...

(0.0% 1d) (-24.3% 1m) (-59.2% 1y) (0.0% 2d) (0.0% 3d) (-4.5% 7d) (-13.61% volume)
Earnings Calendar: 2023-11-06
Market Cap: $ 390,117,343
https://www.biomeafusion.com
Sec Filling | Patents | 12 employees

Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

genetic cancer msa

add to watch list Paper trade email alert is off

Singular Genomics Systems Inc

OMIC | $0.3925 0.93% 0.92% 120K

Professional, Scientific, and T...

(0.0% 1d) (-23.6% 1m) (-61.9% 1y) (0.0% 2d) (0.0% 3d) (6.1% 7d) (-11.2% volume)
Earnings Calendar: 2024-03-18
Market Cap: $ 29,016,959
https://singulargenomics.com
Sec Filling | Patents | 138 employees

Singular Genomics is a life science technology company that is leveraging novel, next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. The Singular Sequencing Engine is the foundational platform technology that forms the basis of Singular Genomics’ products in development and Singular Genomics’ core product tenets: accuracy, speed, flexibility and scale. Singular Genomics’ first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the G4 Integrated Solution. A second integrated solution in development comprises an instrument and an associated menu of consumable kits, which Singular Genomics refers to collectively as the PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution.

t-cell

add to watch list Paper trade email alert is off

Akoya Biosciences Inc

AKYA | $3.81 -1.04% -1.05% 170K

Professional, Scientific, and T...

(0.0% 1d) (-21.0% 1m) (-44.3% 1y) (0.0% 2d) (0.0% 3d) (-0.7% 7d) (100.14% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 187,226,185
https://www.akoyabio.com
Sec Filling | Patents | n/a employees

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

t-cell treatment ceiling

add to watch list Paper trade email alert is off

Reneo Pharmaceuticals Inc

RPHM | $1.74 -1.14% -1.15% 83K

Professional, Scientific, and T...

(0.0% 1d) (6.6% 1m) (-81.9% 1y) (0.0% 2d) (0.0% 3d) (6.6% 7d) (616.69% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 58,152,206
https://reneopharma.com
Sec Filling | Patents | 32 employees

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

energy renewable genetic metabolic

add to watch list Paper trade email alert is off

Panbela Therapeutics Inc

PBLA | $0.4895 -6.31% 66K

Professional, Scientific, and T...

(0.0% 1d) (-18.8% 1m) (-96.3% 1y) (0.0% 2d) (0.0% 3d) (-3.7% 7d) (49.66% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 2,376,454
http://www.sunbiopharma.com/
Sec Filling | Patents | 6 employees

(US) Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. isdedicated to treating patients with pancreatic cancer and exploring SBP-101's potential for efficacy in combination with other agents and in treating other types of cancer.

cancer treatment pancreatic

add to watch list Paper trade email alert is off